Project Grant HT94252310196
Award Date
9/30/23
Completion Date
9/29/25
Dollars Obligated
$950K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Grand Rapids, MI 49503, USA
Similar Awards
This $680,591 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund a research project at Wayfinder Biosciences Inc. in Seattle, WA. The project aims to develop a novel small molecule screening approach for directly and selectively targeting repeat expansion RNA in C9ORF72 amyotrophic lateral sclerosis (ALS). The award period runs from June 15, 2025 to June 14, 2026 and seeks to advance disease prevention,...
This $854,060 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) was provided to Formation Venture Engineering Foundry Inc., a for-profit biotech firm, to develop an FC-fusion protein active vaccine for the prevention and treatment of C9ORF72 ALS/FTD, a rare neurodegenerative disease. The award period is from Apr 15, 2024 to Apr 14, 2026. The Military Medical Research and Development program supports innovative biomedical research...
The Department of the Army Medical Command awarded a $1,210,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Mayo Clinic to conduct research exploring novel biomarkers for amyotrophic lateral sclerosis (ALS). The 3-year grant, titled "Exploring Novel ALS Biomarkers: Multiomics Approach Utilizing Immunoprofiling, Extracellular Vesicle Analysis, and TDP-43 Aggregation Assays," aims to advance the understanding of ALS pathogenesis and identify...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
The U.S. Defense Health Agency has awarded a $602,800 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Vlaams Instituut Voor Biotechnologie (VIB), a non-profit research institute in Belgium. The grant, effective September 1, 2024 through August 31, 2027, will fund VIB's research on a "Reduced Combination of Genetic Variants to Predict and Stratify Alzheimer's Disease." This project aims to advance medical solutions for neurodegenerative...
The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...
The Defense Health Agency awarded a $929,948 Project Grant to The Washington University in St. Louis, Missouri to support the research project "TARGETING TDP-43 MITOCHONDRIAL MISLOCALIZATION IN ALS". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. The research project will investigate mitochondrial...
The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
This federal Project Grant award of $1,078,882.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research focused on developing innovative therapeutic approaches for amyotrophic lateral sclerosis (ALS) by investigating the multimodal therapeutic actions of donor and host neural stem cells. Key research services include consultation on surgical intervention methods for delivering compounds...
This $925,757 Project Grant award, provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program, supports research conducted by Wake Forest University Health Sciences (WFUHS) to selectively reduce repeat expansion RNA with small molecules to treat C9orf72 mediated amyotrophic lateral sclerosis (ALS). The award period runs from April 1, 2025 to March 31, 2027. The funding will enable WFUHS, a private non-profit...